Want to see FR:ALCLS full AI Analyst Report?
ALCLS Stock Chart & Stats
€2.59
<€0.01(0.23%)
At close: 4:00 PM EDT
€2.59
<€0.01(0.23%)
Day’s Range― - ―
52-Week Range€2.03 - €4.84
Previous CloseN/A
Volume109.61K
Average Volume (3M)852.48K
Market Cap
€212.49M
Enterprise Value€205.35
Total Cash (Recent Filing)€166.85M
Total Debt (Recent Filing)€84.57M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Nov 09, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding72,325,455
10 Day Avg. Volume1,338,181
30 Day Avg. Volume852,477
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)6.52
Price to Sales (P/S)6.52
P/FCF Ratio-11.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.74
Revenue Forecast (FY)€52.22M
Bulls Say, Bears Say
Bulls Say
Allogeneic Gene-Edited Cell Therapy PlatformAn allogeneic, off-the-shelf approach could improve the scalability and accessibility of cell therapies versus fully individualized treatments. Cellectis’ gene-editing and cell-engineering capabilities support a focused platform for multiple oncology candidates.
Partner-Based Revenue OpportunitiesThe collaboration model provides several potential monetization routes beyond product sales, including licenses, milestones and royalties. This can diversify funding sources and allow partners to support development before Cellectis reaches commercialization.
Strong Gross Margin ProfileA high gross margin indicates that the underlying technology and partnered activities can retain substantial value after direct costs. If revenue scales through collaborations or successful products, this provides a foundation for operating leverage.
Bears Say
Declining And Volatile RevenueRevenue volatility and the latest decline make it difficult to establish a dependable growth trajectory. This increases uncertainty around partner activity, pipeline progression and the timing at which the company can scale toward sustainable operating profitability.
Persistent Operating LossesLarge losses show that current revenue and gross profit do not cover the company’s research, development and operating cost base. Continued losses could require additional financing and may limit flexibility to advance multiple clinical programs.
Cash Burn And Higher LeverageSizable cash burn combined with a thinner equity cushion increases dependence on external funding. Higher leverage can constrain strategic choices and raise balance-sheet risk if clinical development remains lengthy or partnership proceeds are delayed.
Cellectis SA News
ALCLS FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was €2.03 and its highest was €4.84 in the past 12 months.
What is Cellectis SA’s market cap?
Cellectis SA’s market cap is €212.49M.
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is Nov 09, 2026 which is in 73 days.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on Aug 06, 2026. The company reported -€0.19 earnings per share for the quarter, beating the consensus estimate of -€0.227 by €0.037.
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Overvalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -0.18.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,325,455 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of -€0.19 in its last earnings report, beating expectations of -€0.227. Following the earnings report the stock price went down -0.495%.
Which hedge fund is a major shareholder of Cellectis SA?
Currently, no hedge funds are holding shares in FR:ALCLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectis SA
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.
Technical Analysis
Innate Pharma SA
―
Nanobiotix
―
Transgene
―
OSE Immunotherapeutics SA
―
MaaT Pharma
―